J P Morgan Chase & Co reiterated their neutral rating on shares of GlaxoSmithKline PLC (NYSE:GSK) in a report published on Thursday morning.

A number of other research analysts have also weighed in on the stock. Argus reaffirmed a buy rating and issued a $50.00 price objective on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Morgan Stanley lowered shares of GlaxoSmithKline PLC from an equal weight rating to an underweight rating in a research report on Friday, September 8th. Zacks Investment Research raised shares of GlaxoSmithKline PLC from a hold rating to a buy rating and set a $47.00 price target on the stock in a research report on Tuesday, July 18th. ValuEngine lowered shares of GlaxoSmithKline PLC from a buy rating to a hold rating in a research report on Friday, June 2nd. Finally, BidaskClub raised shares of GlaxoSmithKline PLC from a strong sell rating to a sell rating in a research report on Friday, August 25th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of Hold and an average price target of $44.67.

Shares of GlaxoSmithKline PLC (GSK) opened at 40.58 on Thursday. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.54. The firm has a 50-day moving average of $39.76 and a 200 day moving average of $41.75. The firm has a market capitalization of $99.18 billion, a price-to-earnings ratio of 39.32 and a beta of 1.03.

GlaxoSmithKline PLC (NYSE:GSK) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The firm had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. On average, equities analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “J P Morgan Chase & Co Reaffirms Neutral Rating for GlaxoSmithKline PLC (GSK)” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of international trademark and copyright laws. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/24/j-p-morgan-chase-co-reaffirms-neutral-rating-for-glaxosmithkline-plc-gsk.html.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be issued a dividend of $0.491 per share. This represents a $1.96 dividend on an annualized basis and a yield of 4.84%. The ex-dividend date of this dividend is Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is 197.00%.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Bronfman E.L. Rothschild L.P. increased its stake in shares of GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after purchasing an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its stake in shares of GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after purchasing an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC increased its stake in shares of GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after purchasing an additional 1,990 shares in the last quarter. Heritage Trust Co purchased a new position in shares of GlaxoSmithKline PLC in the first quarter worth about $123,000. Finally, Westwood Holdings Group Inc. increased its stake in shares of GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after purchasing an additional 400 shares in the last quarter. Institutional investors and hedge funds own 9.28% of the company’s stock.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.